Jonathan D. Cogen

Jonathan D. Cogen

Auto-generated profile, based on publicly available information

Jonathan D. Cogen

Division of Pulmonary and Sleep Medicine, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Pediatrics
Verified
Journal Article
Closed access
PDF file
JCJonathan D. Cogen
Jonathan D. Cogen
AOAssaf P. Oron
Assaf P. Oron
RGRonald L. Gibson
Ronald L. Gibson
LHLucas R. Hoffman
Lucas R. Hoffman
MKMatthew P. Kronman
Matthew P. Kronman
MRMargaret Rosenfeld
Margaret Rosenfeld
BACKGROUND AND OBJECTIVES: Pulmonary exacerbations lead to significant morbidity and mortality in patients with cystic fibrosis (CF). National consensus guidelines exist, but few studies report current practice in the treatment and monitoring of pulmonary exacerbations. The goal of this study was to characterize consistency and variability in the inpatient management of CF-related pulmonary exacerbations. We focused on the use of guideline-recommended maintenance therapies, antibiotic selection and treatment regimens, use of systemic corticosteroids, and frequency of lung function testing. We hypothesized that significant variability in these treatment practices exists nationally.METHODS: This trial was a retrospective cross-sectional study. It included patients with CF aged ≤18 years hospitalized for pulmonary exacerbations between July 1, 2010, and June 30, 2015, at hospitals within the US Pediatric Health Information System database that are also Cystic Fibrosis Foundation–accredited care centers. One exacerbation per patient was randomly selected over the 5-year study period.RESULTS: From 38 hospitals, 4827 individual pulmonary exacerbations were examined. Median length of stay was 10.0 days (interquartile range, 6–14.0 days). Significant variation was seen among centers in the use of hypertonic saline (11%–100%), azithromycin (5%–83%), and systemic corticosteroids (3%–61%) and in the frequency of lung function testing. Four different admission antibiotic regimens were used >10% of the time, and the most commonly used admission antibiotic regimen comprised 2 intravenous antibiotics with no additional oral or inhaled antibiotics (29%).CONCLUSIONS: Significant variation exists in the treatment and monitoring of pulmonary exacerbations across Pediatric Health Information System–participating, Cystic Fibrosis Foundation–accredited care centers. Results from this study can inform future research working toward standardized inpatient pulmonary exacerbation management to improve CF care for children and adolescents.

12 January 2024 in Academic Medicine
Verified
Journal Article
Closed access
JCJonathan D. Cogen
Jonathan D. Cogen
APAlexandra Perkins
Alexandra Perkins
BMBlair Mockler
Blair Mockler
KBKrysta S. Barton
Krysta S. Barton
ASAlan Schwartz
Alan Schwartz
OGon behalf of the APPD LEARN Climate Change Study Group
on behalf of the APPD LEARN Climate Change Study Group
Purpose: The American Academy of Pediatrics emphasized in a 2007 policy statement the importance of educating trainees on the impacts of climate change on children’s health, yet few studies have evaluated trainee knowledge and attitudes about climate change–related health effects in children. This multi-institution study assessed pediatric resident and program director (1) knowledge/attitudes on climate change and health, (2) perspectives on the importance of incorporating climate and health content into pediatric graduate medical education, and (3) preferred topics/activities to include in climate and health curricula. Method: This mixed-methods study employed an anonymous cross-sectional survey of pediatric residents and residency program directors from Association of Pediatric Program Directors (APPD) Longitudinal Educational Assessment Research Network (LEARN)–affiliated programs. Multivariable regression models and factor analyses were used to examine associations among resident demographics and resident knowledge, attitudes, and interest in a climate change curriculum. A conventional content analysis was conducted for the open-ended responses. Results: Eighteen programs participated in the study with all program directors (100% response rate) and 663 residents (average response rate per program, 53%; overall response rate, 42%) completing respective surveys. Of the program directors, only 3 (17%) felt very or moderately knowledgeable about the association between climate change and health impacts. The majority of residents (n=423, 64%) agreed/strongly agreed that physicians should discuss global warming/climate change and its health effects with patients/families, while only 138 residents (21%) agreed/strongly agreed that they were comfortable talking with patients and families about these issues. Most residents (n=498, 76%) and program directors (n=15, 83%) agreed/strongly agreed that a climate change curriculum should be incorporated into their pediatrics training program. Conclusions: Pediatric residents and program directors support curricula that prepare future pediatricians to address the impact of climate change on children’s health; however, few programs currently offer specific training, despite identified needs.

1 July 2020 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
JCJonathan D. Cogen
Jonathan D. Cogen
BKBarbara C. Kahl
Barbara C. Kahl
HMHolly Maples
Holly Maples
SMSusanna A McColley
Susanna A McColley
JRJason A. Roberts
Jason A. Roberts
SBScott C Bell
Scott C Bell

15 April 2017 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
SHSonya L. Heltshe
Sonya L. Heltshe
JCJonathan Cogen
Jonathan Cogen
KRKathleen J. Ramos
Kathleen J. Ramos
CGChristopher H. Goss
Christopher H. Goss
Cystic fibrosis (CF) is the most common life shortening monogenetic disorder involving the lung affecting over 70,000 people worldwide. It has now been over 25 years since the identification of the disease-causing gene defect [the gene producing cystic fibrosis transmembrane conductance regulator protein (CFTR)]. Since this discovery, dramatic advances have occurred both in the basic science underpinning our understanding of the clinical presentation of CF, and in clinical outcomes noted by improvement in lung function and survival. Advances in clinical outcomes have come from both improved coordinated clinical care and enhancement of clinical trials in CF. The CF community has two robust clinical trial networks that have permitted successful translation from laboratory science to novel therapeutics in the clinics. To date, 11 medications have approved specifically for CF in either Europe or the United States (US). The most recent of these approvals have been mutation specific therapies now available for over 50% of all CF patients in the US. These novel therapeutics in CF have been transformative, demonstrating how a commitment to basic science can translate into therapeutic advances. The future is very bright for both patients with CF and their families. To continue to make advances that address the primary defect in CF, we are going to need to become both smarter and more agile in our design of clinical trials.

27 April 2024 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
JCJonathan D. Cogen
Jonathan D. Cogen
BQBradley S. Quon
Bradley S. Quon
Pulmonary exacerbations in people with cystic fibrosis are associated with significant morbidity and reduced quality of life. Pulmonary exacerbation treatment guidelines, published by an expert panel assembled by the Cystic Fibrosis Foundation nearly 15 years ago, were primarily consensus-based as there were several gaps in the evidence base. In particular, limited evidence existed regarding optimal pulmonary exacerbation treatment strategies, including duration of antibiotic therapy, treatment location, antibiotic selection, and the role of systemic corticosteroids. Over the last decade, results from observational studies and large multi-center randomized controlled trials have begun to answer important questions related to pulmonary exacerbation treatment. This review focuses on the diagnosis, etiology, and changing epidemiology of pulmonary exacerbations, and also summarizes the most recent and up-to-date studies describing pulmonary exacerbation treatment. Finally, this review provides consideration for future pulmonary exacerbation research priorities, particularly in the current highly effective modulator therapy era.

18 March 2019 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
JCJonathan D. Cogen
Jonathan D. Cogen
MHMatt Hall
Matt Hall
DLDeena R. Loeffler
Deena R. Loeffler
NGNancy Gove
Nancy Gove
FOFrankline Onchiri
Frankline Onchiri
AFAliza K. Fink
Aliza K. Fink